You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
GNS Healthcare will apply its AI and simulation technology to data from the CoMMpass study in search of insights on disease progression and drug response.
The company said it plans to use the technology to derive clinical insights from the large-scale proteomic datasets generated by its SomaScan platform.
Using data from the Parkinson's Progression Markers Initiative, GNS Healthcare identifies genetic and molecular markers of rapid motor progression.
Swedish Cancer Institute has enlisted machine-learning technology vendor GNS Healthcare to model patient-specific breast cancer tumor data.
The companies plan to use machine learning and simulation to study disease drivers and identify existing and new therapies, focusing first on cardiovascular disease.
Most recently, Celgene has licensed the GNS platform for internal use and made an undisclosed equity investment in the company.
The firm will use the funding, which comes from both new and existing investors, to develop new cloud-based solutions for precision medicine.
GNS Healthcare and the Multiple Myeloma Research Foundation to use GNS' informatics solutions to explore genomic and clinical data from the CoMMpass study.
Robert Hoyt has joined GenomeQuest's board of directors
Hoyt is currently Eximo's chief operating officer. Prior to that, he was the general manager of Endeca Technologies which sold to Oracle in 2011.
President Donald Trump might not approve the stricter standards the US Food and Drug Administration is developing for authorizing a SARS-CoV-2 vaccine, according to Politico.
Wired reports that Oxitec has now developed a genetically modified fall armyworm.
A large genetic study finds SARS-CoV-2 viruses with a certain variant are spreading more than others, according to the Washington Post.
In Nature this week: sister-chromatid-sensitive chromosome conformation capture approach, and more.